Synthesis and evaluation of [125I]I-TSA as a brain nicotinic acetylcholine receptor α7 subtype imaging agent

Nuclear Medicine and Biology

Volumn 33, Issue 3, 2006, Pages 311-316

  Ogawa, Mikako ^a   Tatsumi, Ryo ^b   Fujio, Masakazu ^b   Katayama, Jiro ^b   Magata, Yasuhiro ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

125I I TSA; Central nervous system; In vivo evaluation; Nicotinic acetylcholine receptor 7 subtype; Radiosynthesis

Indexed keywords

3' (5 IODOTHIOPHEN 2 YL)SPIRO(1 AZABICYCLO[2.2.2]OCTANE 3,5'[1',3']OXAZOLIDIN) 2' ONE I 125; BROMINE; BUNGAROTOXIN RECEPTOR; IODINE; METHYLLYCACONITINE; NICOTINIC RECEPTOR; RECEPTOR SUBTYPE; TRACER; UNCLASSIFIED DRUG; 3' (5 IODOTHIOPHEN 2 YL)SPIRO(1 AZABICYCLO(2.2.2)OCTANE 3,5' (1',3')OXAZOLIDIN) 2' ONE; 3'-(5-IODOTHIOPHEN-2-YL)SPIRO(1-AZABICYCLO(2.2.2)OCTANE-3,5'-(1',3')OXAZOLIDIN)-2'-ONE; ALPHA-BUNGAROTOXIN RECEPTOR; DIAGNOSTIC AGENT; OXAZOLE DERIVATIVE; QUINUCLIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN; BRAIN REGION; CEREBELLUM; CHEMICAL REACTION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG INHIBITION; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; HIPPOCAMPUS; IMAGING; IN VIVO STUDY; MALE; MEASUREMENT; NONHUMAN; RADIOACTIVITY; RADIOIODINATION; RAT; RECEPTOR BLOCKING; STATISTICAL SIGNIFICANCE; TAIL; ANIMAL; METABOLISM; MOUSE; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; SYNTHESIS;

ANIMALS; BRAIN; MALE; MICE; OXAZOLES; POSITRON-EMISSION TOMOGRAPHY; QUINUCLIDINES; RADIOPHARMACEUTICALS; RECEPTORS, NICOTINIC;

EID: 33646046814     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2005.12.016     Document Type: Article

References (27)

1. Karlin A., and Akabas M.H. Toward a structural basis for the function of nicotinic acetylcholine receptors and their cousins. Neuron 15 (1995) 1231-1244
2. Patrick J., Sequela P., Vernino S., Amador M., Luetje C., and Dani J.A. Functional diversity of neuronal nicotinic acetylcholine receptors. Prog Brain Res 98 (1993) 113-120
3. Gotti C., Fornasari D., and Clementi F. Human neuronal nicotinic receptors. Prog Neurobiol 53 (1997) 199-237
4. Albuquerque E.X., Alkondon M., Pereira E.F., Castro N.G., Schrattenholz A., Barbosa C.T., et al. Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. J Pharmacol Exp Ther 280 (1997) 1117-1136
5. 3H]methyllycaconitine: a new radioligand for labelling alpha7-type neuronal nicotinic acetylcholine receptors. Neuropharmacology 38 (1999) 679-690
6. Martin-Ruiz C.M., Haroutunian V.H., Long P., Young A.H., Davis K.L., Perry E.K., et al. Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia. Biol Psychiatry 54 (2003) 1222-1233
7. Court J., Martin-Ruiz C., Piggott M., Spurden D., Griffiths M., and Perry E. Nicotinic receptor abnormalities in Alzheimer's disease. Biol Psychiatry 49 (2001) 175-184
8. Court J., Spurden D., Lloyd S., McKeith I., Ballard C., Cairns N., et al. Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus. J Neurochem 73 (1999) 1590-1597
9. Espinoza-Fonseca L.M. Molecular docking of four beta-amyloid1-42 fragments on the alpha7 nicotinic receptor: delineating the binding site of the Abeta peptides. Biochem Biophys Res Commun 323 (2004) 1191-1196
10. Wang H.Y., Lee D.H., D'Andrea M.R., Peterson P.A., Shank R.P., and Reitz A.B. Beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem 275 (2000) 5626-5632
11. Martin L.F., Kem W.R., and Freedman R. Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology (Berl) 174 (2004) 54-64
12. Jonnala R.R., and Buccafusco J.J. Relationship between the increased cell surface alpha7 nicotinic receptor expression and neuroprotection induced by several nicotinic receptor agonists. J Neurosci Res 66 (2001) 565-572
13. Dajas-Bailador F.A., Lima P.A., and Wonnacott S. The alpha7 nicotinic acetylcholine receptor subtype mediates nicotine protection against NMDA excitotoxicity in primary hippocampal cultures through a Ca(2+) dependent mechanism. Neuropharmacology 39 (2000) 2799-2807
14. Kaneko S., Maeda T., Kume T., Kochiyama H., Akaike A., Shimohama S., et al. Nicotine protects cultured cortical neurons against glutamate-induced cytotoxicity via alpha7-neuronal receptors and neuronal CNS receptors. Brain Res 765 (1997) 135-140
15. Couturier S., Bertrand D., Matter J.M., Hernandez M.C., Bertrand S., Millar N., et al. A neuronal nicotinic acetylcholine receptor subunit (alpha 7) is developmentally regulated and forms a homo-oligomeric channel blocked by alpha-BTX. Neuron 5 (1990) 847-856
16. Ward J.M., Cockcroft V.B., Lunt G.G., Smillie F.S., and Wonnacott S. Methyllycaconitine: a selective probe for neuronal alpha-bungarotoxin binding sites. FEBS Lett 270 (1990) 45-48
17. Navarro H.A., Zhong D., Abraham P., Xu H., and Carroll F.I. Synthesis and pharmacological characterization of [(125)I]iodomethyllycaconitine ([(125)I]iodo-MLA). A new ligand for the alpha(7) nicotinic acetylcholine receptor. J Med Chem 43 (2000) 142-145
18. James R.W., Bersinger N.A., Schwendimann B., and Fulpius B.W. Characterization of iodinated derivatives of alpha-bungarotoxin. Hoppe Seyler Z Physiol Chem 361 (1980) 1517-1524
19. Pomper M.G., Phillips E., Fan H., McCarthy D.J., Keith R.A., Gordon J.C., et al. Synthesis and biodistribution of radiolabeled alpha 7 nicotinic acetylcholine receptor ligands. J Nucl Med 46 (2005) 326-334
20. Ortells M.O., and Lunt G.G. Evolutionary history of the ligand-gated ion-channel superfamily of receptors. Trends Neurosci 18 (1995) 121-127
21. Tatsumi R., Fujio M., Satoh H., Katayama J., Takanashi S., Hashimoto K., et al. Discovery of the alpha7 nicotinic acetylcholine receptor agonists. (R)-3′-(5-Chlorothiophen-2-yl)spiro-1-azabicyclo[2.2.2]octane-3,5′-[1′,3′] oxazolidin-2′-one as a novel, potent, selective, and orally bioavailable ligand. J Med Chem 48 (2005) 2678-2686
22. Mukhin A.G., Gundisch D., Horti A.G., Koren A.O., Tamagnan G., Kimes A.S., et al. 5-Iodo-A-85380, an alpha4beta2 subtype-selective ligand for nicotinic acetylcholine receptors. Mol Pharmacol 57 (2000) 642-649
23. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 193 (1951) 265-275
24. Cheng Y., and Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22 (1973) 3099-3108
25. 3 receptor using site directed mutagenesis: importance of glutamate 106. Neuropharmacology 36 (1997) 637-647
26. Saji H., Iida Y., Nakatsuka I., Kataoka M., Ariyoshi K., Magata Y., et al. Radioiodinated 2′-iododiazepam: a potential imaging agent for SPECT investigations of benzodiazepine receptors. J Nucl Med 34 (1993) 932-937
27. Waterhouse R.N. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol Imaging Biol 5 (2003) 376-389